Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.
暂无分享,去创建一个
J. Viallard | J. Dantal | I. Marie | J. Crave | P. Cherin | M. Michallet | E. Pelus | J. Delain | Jean-Christophe Delain
[1] G. Ruoppolo,et al. Kawasaki disease: an evolving paradigm. , 2015, Autoimmunity reviews.
[2] G. Zandman-Goddard,et al. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. , 2015, Autoimmunity reviews.
[3] A. Fioravanti,et al. Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. , 2015, Autoimmunity reviews.
[4] S. Spector,et al. Practice parameter for the diagnosis and management of primary immunodeficiency. , 2015, The Journal of allergy and clinical immunology.
[5] T. Kuijpers,et al. On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events , 2015, Front. Immunol..
[6] B. Costa-Carvalho,et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. , 2014, International immunopharmacology.
[7] A. Gabrielli,et al. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. , 2014, Autoimmunity reviews.
[8] D. Zillikens,et al. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. , 2014, JAMA dermatology.
[9] T. Burnouf,et al. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. , 2014, Biologicals : journal of the International Association of Biological Standardization.
[10] E. Herzog,et al. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma , 2014, Vox sanguinis.
[11] A. Borobia,et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. , 2014, Thrombosis research.
[12] J. Franco,et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. , 2014, Allergologia et immunopathologia.
[13] K. Johnston,et al. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke , 2014, Vascular health and risk management.
[14] S. L. Kwong,et al. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study , 2013, Asia Pacific allergy.
[15] J. Dantal. Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk , 2013, American Journal of Nephrology.
[16] K. Hanschmann,et al. Thromboembolic events associated with immunoglobulin treatment , 2013, Vox sanguinis.
[17] E. R. Stiehm,et al. Adverse effects of human immunoglobulin therapy. , 2013, Transfusion medicine reviews.
[18] L. Mouthon,et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations , 2013, Vox sanguinis.
[19] David C. Martin,et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010 , 2012, Transfusion.
[20] H. Ochs,et al. Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis , 2012, Journal of Clinical Immunology.
[21] P. Bentley,et al. Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure , 2012, Journal of clinical pharmacy and therapeutics.
[22] R. Scuccimarri,et al. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases , 2012, Pediatric Rheumatology.
[23] J. Dodt,et al. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products , 2012, Vox sanguinis.
[24] P. Cherin,et al. Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use , 2010, BioDrugs.
[25] Y. Rajabally,et al. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study , 2011, Journal of the Neurological Sciences.
[26] T. Saji,et al. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease , 2011, Pediatric rheumatology online journal.
[27] Hafiz M. R. Khan,et al. The Safety Profile of Home Infusion of Intravenous Immunoglobulin in Patients With Neuroimmunologic Disorders , 2011, Journal of clinical neuromuscular disease.
[28] W. Sewell,et al. Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. , 2011, Drug metabolism letters.
[29] J. Kanellis,et al. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody‐mediated rejection , 2011, Nephrology.
[30] G. Verleden,et al. REPEATED, SEVERE HEADACHE IN A LUNG TRANSPLANT PATIENT : A CASE REPORT , 2010, Acta clinica Belgica.
[31] D. Keskin,et al. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. , 2010, Autoimmunity reviews.
[32] Kathleen C. Williams,et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. , 2010, Clinical immunology.
[33] S. Jordan,et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[34] H. Ochs,et al. Subcutaneous immunoglobulin: opportunities and outlook , 2009, Clinical and experimental immunology.
[35] S. Miescher,et al. In vitro comparison of the complement‐scavenging capacity of different intravenous immunoglobulin preparations , 2009, Vox sanguinis.
[36] S. Fedele,et al. Analysis of thromboembolic risk related to high‐dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases , 2009, Clinical and experimental dermatology.
[37] L. Hobson‐Webb,et al. Case-control study of thromboembolic events associated with IV immunoglobulin , 2009, Journal of Neurology.
[38] N. Pouladi,et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. , 2009, Journal of investigational allergology & clinical immunology.
[39] M. Eibl. History of immunoglobulin replacement. , 2008, Immunology and allergy clinics of North America.
[40] J. Hooper. Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations , 2008, Immunology and Allergy Clinics of North America.
[41] R. Padmore,et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.
[42] B. Wolach,et al. Transfusion‐related acute lung injury following intravenous anti‐D administration in an adolescent , 2008, American journal of hematology.
[43] A. Alangari,et al. Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia. , 2008, Saudi medical journal.
[44] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[45] M. Longy-Boursier,et al. Effets indésirables liés aux immunoglobulines humaines normales: intérêt des mesures de prévention. , 2008 .
[46] H. Gürcan,et al. Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid , 2007, The Annals of pharmacotherapy.
[47] A. Fasth,et al. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency , 2007, Acta paediatrica.
[48] K. Stylianou,et al. Acute Renal Failure, Translocational Hyponatremia and Hyperkalemia following Intravenous Immunoglobulin Therapy , 2007, Nephron Clinical Practice.
[49] M. Ballow. Safety of IGIV therapy and infusion-related adverse events , 2007, Immunologic research.
[50] F. Fakhouri. [Intravenous immunoglobulins and acute renal failure: mechanism and prevention]. , 2007, La Revue de medecine interne.
[51] R. Sorensen. Expert Opinion Regarding Clinical and Other Outcome Considerations in the Formulary Review of Immune Globulin , 2007, Journal of managed care pharmacy : JMCP.
[52] F. Fakhouri. Immunoglobulines intraveineuses et insuffisance rénale : mécanisme et prévention , 2007 .
[53] S. Fedele,et al. Variations in Serum Hemoglobin, Albumin, and Electrolytes in Patients Receiving Intravenous Immunoglobulin Therapy , 2007, American journal of clinical dermatology.
[54] S. Miescher,et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. , 2006, Blood.
[55] F. Haramburu,et al. Tolérance des immunoglobulines polyvalentes, impact de l'utilisation d'un protocole de prescription sur la survenue d'effets indésirables liés au traitement , 2006 .
[56] I. Marie,et al. Intravenous immunoglobulin-associated vena cava thrombosis , 2006, Thrombosis and Haemostasis.
[57] I. Marie,et al. Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.
[58] S. Jordan,et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[59] H. Ochs,et al. Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases , 2006, Journal of Clinical Immunology.
[60] A. Rastogi,et al. True hyponatremia secondary to intravenous immunoglobulin , 2006, Clinical and Experimental Nephrology.
[61] B. Reid,et al. Protocol Recommendations for Administration of Intravenous Immunoglobulin in Canada , 2006, Journal of infusion nursing : the official publication of the Infusion Nurses Society.
[62] Ó. Asensio,et al. Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National Study , 2006, Journal of Clinical Immunology.
[63] D. Singh-Grewal,et al. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions , 2006, Archives of Disease in Childhood.
[64] D. Hamrock,et al. Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.
[65] J. Orange,et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.
[66] J. Siegel. Safety considerations in IGIV utilization. , 2006, International immunopharmacology.
[67] A. Achiron,et al. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience , 2006, Autoimmunity.
[68] Y. Shoenfeld,et al. Intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.
[69] J. Siegel. The Product: All Intravenous Immunoglobulins Are Not Equivalent , 2005, Pharmacotherapy.
[70] M. Borte,et al. [Treatment of patients with primary antibody deficiencies in Germany]. , 2005, Klinische Padiatrie.
[71] R. Ben-Ami,et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins , 2005 .
[72] T. Trujillo,et al. Intravenous Immunoglobulin–Associated Acute Renal Failure: Case Series and Literature Review , 2005, Pharmacotherapy.
[73] V. Moalic,et al. Syndrome de détresse respiratoire aiguë post-transfusionnel : une pathologie méconnue , 2005 .
[74] L. Raffini,et al. Neutropenia Following IVIG Therapy in Pediatric Patients With Immune-Mediated Thrombocytopenia , 2005, Journal of pediatric hematology/oncology.
[75] C. Férec,et al. [Transfusion related acute lung injury (TRALI): an unrecognised pathology]. , 2005, Pathologie-biologie.
[76] Y. Shoenfeld,et al. Intravenous immunoglobulin and the kidney--a two-edged sword. , 2004, Seminars in arthritis and rheumatism.
[77] S. Chapman,et al. Acute Renal Failure and Intravenous Immune Globulin: Occurs with Sucrose-Stabilized, but Not with D-Sorbitol–Stabilized, Formulation , 2004, The Annals of pharmacotherapy.
[78] Ó. Asensio,et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. , 2004, The Journal of allergy and clinical immunology.
[79] C. Pozzilli,et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial , 2004, The Lancet.
[80] M. Aihara,et al. An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment , 2004, Modern rheumatology.
[81] F. Bonilla. PROSPECTIVE AUDIT OF ADVERSE REACTIONS OCCURRING IN 459 PRIMARY ANTIBODY-DEFICIENT PATIENTS RECEIVING INTRAVENOUS IMMUNOGLOBULIN , 2004, Pediatrics.
[82] M. Berger. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.
[83] M. Dalakas,et al. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, Pharmacology & therapeutics.
[84] J. Sinclair,et al. Increased risk of adverse events when changing intravenous immunoglobulin preparations , 2004, Clinical and experimental immunology.
[85] D. Ericson,et al. The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy , 2000, Journal of Clinical Immunology.
[86] Y. Shoenfeld,et al. Anti-DNA and Antiphospholipid Antibodies in IVIG Preparations: In Vivo Study in Naive Mice , 2004, Journal of Clinical Immunology.
[87] T. Hashimoto,et al. Neutropenia as a Complication of High-Dose Intravenous Immunoglobulin Therapy in Adult Patients With Neuroimmunologic Disorders , 2003, Clinical neuropharmacology.
[88] R. Geha,et al. The X-Linked Hyper-IgM Syndrome: Clinical and Immunologic Features of 79 Patients , 2003, Medicine.
[89] N. Jain,et al. Risks associated with the use of intravenous immunoglobulin. , 2003, Transfusion medicine reviews.
[90] M. Kruskall,et al. Intravenous immune globulins: an update for clinicians , 2003, Transfusion.
[91] M. Dalakas,et al. Strokes, thromboembolic events, and IVIg , 2003, Neurology.
[92] M. Cartwright,et al. The clinical features of 16 cases of stroke associated with administration of IVIg , 2003, Neurology.
[93] D. Okuda,et al. Arterial thrombosis induced by IVIg and its treatment with tPA , 2003, Neurology.
[94] S. Ford,et al. Intravenous immunoglobulin therapy results in post‐infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia , 2003, American journal of hematology.
[95] J. V. D. van der Meer,et al. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. , 2003, The Netherlands journal of medicine.
[96] N. Evangelou,et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk–benefit assessment for immunoglobulin treatment , 2003, Journal of clinical pathology.
[97] P. Korenblat,et al. A randomized double-blind trial , 2003 .
[98] T. Brannagan. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies , 2002, Neurology.
[99] C. Cunningham-Rundles,et al. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. , 2002, The Journal of allergy and clinical immunology.
[100] R. Hughes,et al. Intravenous immunoglobulin in neurological disease: a specialist review , 2002, Journal of neurology, neurosurgery, and psychiatry.
[101] L. Watson,et al. Intravenous Immunoglobulin-Related Acute Coronary Syndrome and Coronary Angiography in Idiopathic Thrombocytopenic Purpura , 2002, Angiology.
[102] C. Cunningham-Rundles,et al. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. , 2001, Clinical immunology.
[103] J. Lewis,et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders , 2001, Neurology.
[104] G. Comi,et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.
[105] L. Rauova,et al. Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases , 2001, Pharmacology.
[106] R. Weinstein,et al. Transfusion‐related acute lung injury after the infusion of IVIG , 2001, Transfusion.
[107] J. Levy,et al. Nephrotoxicity of intravenous immunoglobulin. , 2000, QJM : monthly journal of the Association of Physicians.
[108] A. Wolberg,et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations , 2000, American journal of hematology.
[109] Epstein Js,et al. Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. , 2000 .
[110] T. Taga,et al. Severe hemolytic anemia following high‐dose intravenous immunoglobulin administration in a patient with Kawasaki Disease , 2000, American journal of hematology.
[111] W. Sewell,et al. Drug-Induced Aseptic Meningitis , 2000, Drug safety.
[112] M. Yaron,et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases , 2000, Annals of the rheumatic diseases.
[113] K. Zoon,et al. Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. , 2000, Neonatal network : NN.
[114] M. Dalakas. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. , 1999, Muscle & nerve.
[115] M. Sturzenegger,et al. Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.
[116] S. Ng. Intravenous immunoglobulin infusion causing pseudohyponatremia , 1999, Lupus.
[117] C. Cunningham-Rundles,et al. Common variable immunodeficiency: clinical and immunological features of 248 patients. , 1999, Clinical immunology.
[118] P G Shekelle,et al. Developing clinical guidelines. , 1999, The Western journal of medicine.
[119] M. Berkovitch,et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. , 1999, International journal of immunopharmacology.
[120] P. Eggimann,et al. High-Dose Intravenous Immunoglobulin Treatment and Cerebral Vasospasm: A Possible Mechanism of Ischemic Encephalopathy? , 1999, European Neurology.
[121] E. Wegmüller. Effect of intravenous immunoglobulin therapy on plasma complement. , 1998, Transfusion science.
[122] Fontana,et al. High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo , 1998, Scandinavian journal of immunology.
[123] J. Muir,et al. Une cause rare d'hémorragie intra-alvéolaire: l'accident transfusionnel avec leucoagglutination par anticorps antigranuleux (syndrome Trali) , 1998 .
[124] A. Cuvelier,et al. [A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)]. , 1998, La Revue de medecine interne.
[125] J. Howard,et al. Successful Treatment of Headache Related to Intravenous Immunoglobulin With Antimigraine Medications , 1998, Headache.
[126] R. Mamidi,et al. IVIG Adverse Reactions: Potential Role of Cytokines and Vasoactive Substances , 1998, Vox Sanguinis.
[127] H. Hartung,et al. Intravenous immunoglobulin treatment of neurological autoimmune diseases , 1998, Journal of the Neurological Sciences.
[128] A. Achiron. Complications of intravenous immune globulin treatment in neurologic disease , 1997, Neurology.
[129] John R. Wilson,et al. Hemolytic anemia associated with intravenous immunoglobulin , 1997, Muscle & nerve.
[130] M. Dalakas. Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.
[131] W. Hacke,et al. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .
[132] U. Nydegger. Safety and side effects of i.v. immunoglobulin therapy. , 1996, Clinical and experimental rheumatology.
[133] D. Stroncek,et al. Neutropenia in a patient receiving intravenous immune globulin , 1996, Journal of Neuroimmunology.
[134] T. Yousry,et al. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin , 1996, Neurology.
[135] T. Ratko,et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. , 1995, JAMA.
[136] M. Dalakas. Aseptic Meningitis and Intravenous Immunoglobulin Therapy , 1995, Annals of Internal Medicine.
[137] R. I. Schiff. Transmission of viral infections through intravenous immune globulin. , 1994, The New England journal of medicine.
[138] N. Liabakk,et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. , 1994, Blood.
[139] M. Dalakas,et al. Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors , 1994, Annals of Internal Medicine.
[140] C. Duhem,et al. Side-effects of intravenous immune globulins. , 1994, Clinical and experimental immunology.
[141] M. Swenson,et al. Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis , 1994, Muscle & nerve.
[142] M. Dalakas. High‐dose intravenous immunoglobulin and serum viscosity , 1994, Neurology.
[143] F. Retornaz,et al. Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura , 1993, American journal of hematology.
[144] L. McCluskey,et al. Recurrent migraine and intravenous immune globulin therapy. , 1993, The New England journal of medicine.
[145] Z. Meiner,et al. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[146] P. Cherin,et al. Ischemic Vernet's syndrome in giant cell arteritis: first two cases. , 1992, The American journal of medicine.
[147] W. Reinhart,et al. Effect of high-dose intravenous immunoglobulin therapy on blood rheology , 1992, The Lancet.
[148] S. Miller,et al. Intravenous immune globulin and aseptic meningitis. , 1992, American journal of diseases of children.
[149] J. Dwyer. Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.
[150] J. Piette,et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. , 1991, The American journal of medicine.
[151] L. Mofenson,et al. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. , 1991, The New England journal of medicine.
[152] R. Buckley,et al. The use of intravenous immune globulin in immunodeficiency diseases. , 1991, The New England journal of medicine.
[153] U. Nydegger,et al. Defining the Specificity of Anti‐A/B IgM/G Antibodies with Different Antigens and Lectins 1 , 1991, Vox sanguinis.
[154] Intravenous immunoglobulin: prevention and treatment of disease. Summary of the NIH Consensus Development Conference. , 1991, Transfusion medicine reviews.
[155] B. Wechsler,et al. Intravenous immunoglobulin for polymyositis and dermatomyositis , 1990, The Lancet.
[156] S. Okubo,et al. Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody , 1990, Transfusion.
[157] A. Randomized. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .
[158] C. Hosking,et al. Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: A controlled trial , 1988, Australian paediatric journal.
[159] G. Herrera,et al. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. , 1987, The American journal of medicine.
[160] A. Grigg,et al. FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS , 1986, The Lancet.
[161] A. Burks,et al. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. , 1986, The New England journal of medicine.
[162] H. Levison,et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. , 1985, The American journal of medicine.
[163] J. Winkelstein,et al. X‐Linked Agammaglobulinemia: An Analysis of 96 Patients , 1985, Medicine.
[164] Katsuko Sato,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.
[165] H. Ochs,et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. , 1982, Clinical immunology and immunopathology.
[166] A. Hirt,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.